COSCIENS Biopharma Inc.
CSCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7,150 | $14,674 | $14,949 | $13,903 |
| - Cash | $16,393 | $6,678 | $10,176 | $6,103 |
| + Debt | $2,310 | $1,698 | $1,930 | $2,078 |
| Enterprise Value | -$6,933 | $9,694 | $6,703 | $9,878 |
| Revenue | $13,783 | $7,143 | $14,572 | $13,486 |
| % Growth | 93% | -51% | 8.1% | – |
| Gross Profit | $6,799 | $2,938 | $8,556 | $8,210 |
| % Margin | 49.3% | 41.1% | 58.7% | 60.9% |
| EBITDA | -$13,489 | -$2,791 | $6,139 | $4,181 |
| % Margin | -97.9% | -39.1% | 42.1% | 31% |
| Net Income | -$15,309 | -$3,485 | $3,448 | $2,640 |
| % Margin | -111.1% | -48.8% | 23.7% | 19.6% |
| EPS Diluted | -5.93 | -1.89 | 2.5 | 1.69 |
| % Growth | -213.8% | -175.6% | 47.9% | – |
| Operating Cash Flow | -$14,568 | -$2,582 | $5,229 | $2,753 |
| Capital Expenditures | -$1,161 | -$722 | -$11 | -$556 |
| Free Cash Flow | -$15,729 | -$3,304 | $4,925 | $2,197 |